GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BioForce Nanosciences Holdings BFNH · USD

Consumer Staples · US listing · 🇺🇸 United States

Compare

6.69

+0.15%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$1.3m

FY2016FY2025

Free cash flow

−$65,150

FY2016FY2025

Shareholders' equity

−$618,543

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue——————$17,775$16,310$4,500$8,250
Gross profit——————$4,360$4,665$1,255$2,250
Operating income−$489,951−$490,437−$471,953−$485,514−$501,955−$158.4m−$46,538−$66,740−$31,261−$2,500
Net income−$1.3m−$490,437−$471,953−$485,514−$501,955−$158.4m−$46,538−$67,738−$31,261−$2,500
Diluted earnings per share-0.04-0.02-0.02-0.02-0.02-5.41-0.00-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$786$862$638$734$11,145$39,865$58,895$35,127$20,908$16,408
Cash and short-term investments$786$862$638$734$11,105$39,865$52,895$29,392$14,325$14,325
Total liabilities$619,329$2.3m$1.8m$1.3m$873,008$399,773$11,587$5,323$12,706$14,123
Debt—$274,101$220,702$174,096$116,178$67,166———$500
Shareholders' equity−$618,543−$2.3m−$1.8m−$1.3m−$861,863−$359,908$47,308$29,804$8,202−$20,946
Shares outstanding34m29m29m29m29m29m15m76m15m7m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$65,150−$61,250−$46,702−$68,389−$77,772−$80,196−$24,383−$62,466−$25,898$1,750
Free cash flow−$65,150−$61,250−$46,702−$68,389−$77,772−$80,196−$24,383−$62,466−$25,898$1,750

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−$262,330−$117,733−$117,798−$115,915−$122,781−$133,457−$123,160−$122,024
Net income$238,682−$102,411−$118,605−$115,915−$122,781−$934,650−$123,160−$122,024
Diluted earnings per share0.01-0.00-0.00-0.00-0.00-0.03-0.00-0.00
Total assets$2.4m$6,347$786$784$905$13,799$862$1,635
Cash and short-term investments$307$6,347—$784$905$13,799—$1,635
Debt—$99,763—$68,213$57,213$42,214—$260,039
Shareholders' equity$2.3m−$720,954−$618,543−$499,938−$384,023−$261,242−$2.3m−$2.2m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income0.3%-68.5%69.5%
Net income38.6%-61.8%86.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2019FY2018FY2017
Price to earnings-6.0-8.1-32.1-15.0-5.5-0.3-0.5-0.1
Price to sales—————0.72.21.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return3%-55%37%204%5982%52%219%401%107700%6300%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 5-to-1 reverse split · 28 Feb 2020
  • 2-for-1 split · 1 Feb 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.